Inside the Deal: Louis Capital's Robbert Van Batenburg on obstacles of a Pfizer/Wyeth merger

  Share     E-Mail    Discussion (3)
Published March 12, 2009 at 9:43 AM

Pfizer Inc. hopes to close its $68 billion deal to buy Wyeth by the end of 2009. To get there it will have to pass muster with antitrust regulators and credit agencies. Then the real work of integration begins. In this edition of Inside the Deal, Robbert Van Batenburg, head of equity research for Louis Capital Markets, tells Suzanne Stevens that the stakes for both companies are high. But with its patent on the blockbuster Lipitor set to expire in 2010 and a limited pipeline to offset the loss, the risks of the deal collapsing would be particularly damaging for Pfizer.

Also see: 
Pfizer's Kindler offers Wyeth integration preview
Merck spends $130M as it enters risky market

Continue reading below


Comments

From: Robert Smith,

I think this merger would be a great move for both companies. I, for one, hope the deal goes through without too much trouble.

Posted on: July 1, 2009 10:56 AM


From: Robert Smith,

...and in this economy, I feel like this would be a huge help the ensure the future of both of this large companies :-)

Posted on: July 1, 2009 11:00 AM


From: Rebecca White,

Pfizer is a very strong company that would be made even stronger by the merger with Wyeth.

Posted on: July 7, 2009 3:51 PM


Post a comment



©Copyright 2010, The Deal, LLC. All rights reserved. Please send all technical questions, comments or concerns to the Webmaster.